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Abstract
Aims/hypothesis Diabetic retinopathy is a progressive neuro-
degenerative disease, but the underlying mechanism is still
obscure. Here, we focused on oxidative stress in the retina,
and analysed its influence on retinal neurodegeneration, using
an antioxidant, lutein.
Methods C57BL/6 mice with streptozotocin-induced dia-
betes were constantly fed either a lutein-supplemented diet
or a control diet from the onset of diabetes, and their
metabolic data were recorded. In 1-month-diabetic mice,
reactive oxygen species (ROS) in the retina were measured
using dihydroethidium and visual function was evaluated
by electroretinograms. Levels of activated extracellular
signal-regulated kinase (ERK), synaptophysin and brain-
derived neurotrophic factor (BDNF) were also measured by
immunoblotting in the retina of 1-month-diabetic mice. In
the retinal sections of 4-month-diabetic mice, histological
changes, cleaved caspase-3 and TUNEL staining were
analysed.
Results Lutein did not affect the metabolic status of the
diabetic mice, but it prevented ROS generation in the retina
and the visual impairment induced by diabetes. ERK
activation, the subsequent synaptophysin reduction, and
the BDNF depletion in the diabetic retina were all
prevented by lutein. Later, in 4-month-diabetic mice, a
decrease in the thickness of the inner plexiform and nuclear
layers, and ganglion cell number, together with increase in
cleaved caspase-3- and TUNEL-positive cells, were
avoided in the retina of lutein-fed mice.
Conclusions/interpretation The results indicated that local
oxidative stress that has a neurodegenerative influence in
the diabetic retina is prevented by constant intake of a
lutein-supplemented diet. The antioxidant, lutein may be a
potential therapeutic approach to protect visual function in
diabetes.
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AT1R Angiotensin II type 1 receptor
BDNF Brain-derived neurotrophic factor
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ERK Extracellular signal-regulated kinase
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INL Inner nuclear layer
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ONL Outer nuclear layer
OP Oscillatory potential
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Introduction
Diabetic retinopathy is considered a neurodegenerative
disease in which visual dysfunction is initiated in early
diabetes [1]. As recent studies reveal, many of the diabetic
complications are associated with oxidative stress [2–4] as
well as inflammation [4, 5]. However, the underlying
mechanism in diabetic retinal degeneration remains to be
elucidated. Moreover, a definitive therapy for its prevention
is not available at this time.
Several intracellular signalling pathways downstream
of inflammation are associated with oxidative stress
[4–7]. One such pathway, angiotensin II type 1 receptor
(AT1R) signalling, is pathogenic in the development of
diabetic complications [3, 8]. In fact, the streptozotocin
(STZ)-induced mouse model of diabetes has a decrease in
responses of the oscillatory potentials (OPs) in electro-
retinograms (ERGs) through retinal AT1R signalling, as we
have previously reported [8]. Another report showed that an
angiotensin II converting enzyme inhibitor prevented the
OP changes, supporting the idea that angiotensin II signal is
important in diabetic retinopathy [9]. OPs reflect the
functioning of the inner retina [10], and are already abnormal
in early diabetes, in both human patients and experimental
animals [8, 11–13]. This is at least in part because of the
decrease in the level of synaptophysin caused by AT1R
signalling in the retina [8]. Synaptophysin is a synaptic
membrane protein that is abundant in the inner plexiform
layer (IPL), where AT1R is also produced [14], and plays a
critical role in OPs. In neurons, AT1R signalling activates
extracellular signal-regulated kinase (ERK) to induce exces-
sive degradation of synaptophysin, through the ubiquitin–
proteasome system [8]. Therefore, AT1R signalling is one of
the key modulators of diabetic retinopathy. However,
whether or not these diabetic neurodegenerative changes
can be prevented by suppressing reactive oxygen species
(ROS) in the retina remains to be elucidated. On the other
hand, retinal ganglion cells [15–18] and a subset of amacrine
cells in the inner nuclear layer (INL) [19] are lost to
apoptosis in diabetes, as shown by caspase-3 activation and
TUNEL staining, and can be attenuated by administration of
the soluble factor, brain-derived neurotrophic factor (BDNF)
[19]. However, the relationship between BDNF and oxida-
tive stress in diabetes is still obscure. Thus, evaluating the
contribution of ROS in diabetic retinopathy may help
establish a new therapy.
Here, we focus on lutein, a xanthophyll carotenoid and an
antioxidant, which is spread throughout the retina. Lutein is
not synthesised in vivo and needs to be obtained through the
diet, and is then delivered to the retina. It corresponds to the
macular pigment in the retina with its optical isomer
zeaxanthin. Long-term oral intake of lutein is reported to
elevate serum lutein levels [20, 21], which correlate with the
macular pigment density [20, 22], indicating that lutein
constantly taken from the diet accumulates in the retina. Our
previous data confirmed that lutein administration increases
lutein levels in the choroid and retinal pigment epithelial
cells in the eye, and suppresses inflammatory signalling in a
model of laser-induced choroidal neovascularisation [7]. We
previously reported in an endotoxin-induced uveitis model
that lutein administration suppresses ROS and inflammatory
signalling in the retina, and prevents the visual dysfunction
[6] caused by rhodopsin degradation [23]. Therefore,
growing evidence shows the role of lutein as a suppressor
of ROS induced by inflammation [6, 7, 24, 25]. However,
the effect of this antioxidant, lutein, in diabetic neuro-
degeneration is not fully understood.
In this study, we analysed whether constant lutein intake
suppresses the neurodegenerative changes in the retina of
STZ-induced diabetic mice. We first checked body weight
or blood glucose level changes and the level of ROS
generated in the retina of diabetic mice, with or without
constant intake of lutein-supplemented diet. Then, visual
function was measured, and biochemical and histological
changes in the retina were analysed. We showed the
neurodegenerative influence of oxidative stress in the
diabetic retina that provides us with a possible mechanism
involved in the pathogenesis of diabetic retinopathy.
Methods
Animals All animal experiments described in this study
were conducted in accordance with the Association for
Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research.
Diabetes was induced in 8-week-old C57BL/6 mice
(Clea Japan, Tokyo, Japan) by daily i.p. injections of STZ
(Sigma-Aldrich, St Louis, MO, USA) at a dose of 60 mg/kg
body weight for 3 days. The blood glucose concentration
was measured from a tail vein using a Medisafe Mini GR-
102 (Terumo, Tokyo, Japan). The development of diabetes
was defined as blood glucose >13.9 mmol/l (250 mg/dl)
7 days after the first injection of STZ. From then on,
diabetic mice were constantly fed a 0.1% (wt/wt) lutein diet
prepared by adding lutein (provided by Wakasa Seikatsu
Co., Kyoto, Japan) to the mouse chow (purchased from
Clea Japan), or the same chow with no additional lutein,
until the time of analysis. These mice, and age-matched
non-diabetic control mice, were then analysed 1 or 4 months
after diabetes induction. Non-diabetic mice fed a lutein-
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supplemented diet were analysed, but there were no
differences compared with the non-diabetic mice fed a
control diet. Therefore, we show as controls the data from
non-diabetic mice fed a control diet.
Measurement of ROS Eyes were enucleated and immedi-
ately frozen in OCT compound (Sakura Finetek, Torrance,
CA, USA). Unfixed cryosections (10 μm) were incubated
with dihydroethidium (DHE; Invitrogen-Molecular Probes,
Eugene, OR, USA) (5 μmol/l) for 20 min at 37°C, as
previously described [6]. DHE specifically reacts with
intracellular superoxide anion and is converted to the red
fluorescent compound ethidium in nuclei. The sections
were examined using a microscope equipped with a digital
camera (Carl Zeiss, Jena, Germany) in the same exposure
conditions, and the intensity of the staining in the INL was
measured in the posterior retina at four points, two on either
side of the optic nerve that were 200 and 500 μm apart,
using the Image J program (version 1.37; National Institutes
of Health, Bethesda, MD, USA). All the procedures in each
sample, from preparing animals to taking photographs,
were performed at the same time in parallel.
ERG analyses Animals were dark-adapted for 12 h and
prepared for the ERG procedure under dim red illumina-
tion. The mice were anaesthetised with pentobarbital
sodium at a dose of 70 mg/kg body weight and placed on
a heating pad that maintained their body temperature at 35–
36°C throughout the experiment. The pupils were dilated
with a solution of 0.5% (wt/vol.) tropicamide and 0.5% (wt/
vol.) phenylephrine (Mydrin-P; Santen, Osaka, Japan). The
ground electrode was a subcutaneous needle in the tail, and
the reference electrode was placed subcutaneously between
the eyes. The active contact lens electrodes (Mayo, Inazawa,
Japan) were placed on the cornea. The recordings were
performed with a PowerLab system 2/25 (AD Instruments,
Bella Vista, NSW, Australia). The responses were differen-
tially amplified with a gain of 1,000 using alternating
current-coupled bioamplifier ML132 (AD Instruments) and
filtered through a bandpass filter ranging from 0.3 to 500 Hz
to yield a- and b-waves. The OPs were simultaneously
recorded using a high-pass filter set to 100 Hz, so that an
overall bandpass ranging from 100 to 500 Hz was achieved.
Light pulses of 800 cd-s/m2 were delivered via a Ganzfeld
System SG-2002 (LKC Technologies; Gaithersburg, MD,
USA). With this system, OP1 is not separated from the
a-wave response; thus we analysed amplitudes and implicit
times of OP2, 3 and 4. The amplitude of total OPs was
calculated by adding those of OP2, 3, and 4.
Immunoblot analyses Isolated retinas were placed into lysis
buffer (10 mmol/l TRIS–HCl [pH 7.6], 100 mmol/l NaCl,
1 mmol/l EDTA, 1% [wt/vol.] Triton X-100 and protease
inhibitors). Each sample was separated by SDS-PAGE and
electroblotted onto a polyvinylidene fluoride membrane
(Millipore, Bedford, MA, USA). After being blocked in
4% (wt/vol.) skimmed milk, the membrane was incubated
at 4°C overnight with rabbit anti-phosphorylated ERK
(1:1,000; Cell Signaling Technology, Beverly, MA, USA),
mouse anti-synaptophysin (1:500; Sigma-Aldrich), rabbit
anti-BDNF (1:500; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or mouse anti-α-tubulin (1:2,000; Sigma-
Aldrich) antibodies. The membrane was then incubated with
a horseradish peroxidase-conjugated antibody against mouse
immunoglobulins or with a biotinylated secondary antibody
against rabbit immunoglobulins followed by avidin–biotin
horseradish peroxidase complex (Vectastain Elite ABC Kit;
Vector, Burlingame, CA, USA). The signals were visualised
by chemiluminescence (ECL Blotting Analysis System;
Amersham, Arlington Heights, IL, USA), measured by
Image J software, and normalised to α-tubulin.
Structural analyses and immunohistochemistry Retinas
were fixed with 4% (wt/vol.) paraformaldehyde and
prepared for paraffin sectioning. All sections (6 μm) were
cut tangentially through the pupil and optic nerve, passing
through the temporal ora serrata, the optic nerve and the
nasal ora serrata. These paraffin sections cut at the centre of
the eye were stained with haematoxylin and eosin. The
thicknesses of the IPL, INL and outer nuclear layer (ONL)
were measured in the posterior retina at four points, two on
either side of the optic nerve that were 200 and 500 μm
apart, using the Image J program. Thicknesses of IPL and
INL were normalised to that of ONL at each point, to
further standardise for bias introduced by skewed section-
ing angle and to more precisely compare the length
between the different sections. Previous reports show that
ONL thickness [15] is not changed in the diabetic retina,
although inner retinal thickness and, consequently, total
retinal thickness are reduced by diabetes [4, 15]. The
neuronal cell number in the ganglion cell layer (GCL) was
quantified by counting the nuclei. For each sample, three
sections were analysed and averaged.
To detect cleaved caspase-3, unstained sections were
subjected to heat-induced antigen retrieval in a microwave
oven for 5min in 10mmol/l citrate buffer, and the endogenous
peroxidase was abolished by incubating the sections in
3% (wt/vol.) hydrogen peroxide in methanol for 10 min.
Sections were incubated in blocking solution (10% normal
bovine serum in PBS) and then incubated with a rabbit
anti-cleaved caspase-3 antibody (1:100; Cell Signaling
Technology), followed by a biotinylated secondary anti-
body and avidin–biotin horseradish peroxidase complexes
(Vectastain Elite ABC Kit). The reaction product was
developed by incubation for 10 min in Tyramide Signal
Amplification Solution (Perkin Elmer Life Sciences,
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Boston, MA, USA), and the nuclei were counterstained
with the nuclear dye bisbenzimide, diluted 1:1,000 from a
10 mg/ml stock solution (Hoechst 33258; Sigma-Aldrich)
to check the retinal cell layers. Apoptotic cells were also
detected in the sections using a TUNEL kit (Chemicon-
Millipore, Billeria, MA, USA). Cleaved caspase-3- or
TUNEL-positive cells in the GCL were counted as described
above.
All the sections were examined using a microscope
equipped with a digital camera (Carl Zeiss).
Statistical analysis Data are expressed as means±SD.
Statistical significance was tested with a one-way ANOVA
with Tukey’s post hoc test, and differences were considered
statistically significant at p<0.05.
Results
Systemic effects of constant lutein intake in diabetic
mice Mice with STZ-induced diabetes, fed either control
or lutein-supplemented diet, showed a significant decrease
in body weight and a significant increase in blood glucose,
compared with age-matched non-diabetic controls (Table 1).
Treatment with a constant lutein diet for 1 or 4 months did
not significantly change these metabolic variables in the
diabetic mice.
Diabetes-induced oxidative stress in the retina was prevented
by lutein To show the levels of ROS generated in the retina,
we performed a DHE reaction that detects one of the ROS,
superoxide anion, in the tissue. DHE staining was observed
in all the layers of the retinas of 1-month-diabetic mice fed
a control diet (Fig. 1a, b); however, it was suppressed
throughout the retina in diabetic mice that had been fed
only with a lutein diet from the onset.
Therefore, diabetes-induced oxidative stress in the retina
was efficiently reduced by constant lutein intake.
Diabetes-induced visual impairment was suppressed by
lutein To determine the effect of constant lutein intake on
visual function in diabetes, we measured ERGs in 1-month-
diabetic mice (Fig. 2a, b). The amplitude of the OPs (OP3
and total OPs), which reflects the functional status of the
inner retina, was decreased in the diabetic mice. However,
reduction in the OP amplitudes was successfully prevented
Duration Diet n Body weight (g) Blood glucose (mmol/l)
1 month
Non-diabetic Control 13 26.7±1.8 8.0±1.1
Diabetic Control 14 23.6±1.3** 29.3±3.8**
Diabetic Lutein 13 23.7±2.0** 28.2±5.1**
4 months
Non-diabetic Control 11 32.5±2.0 9.4±1,5
Diabetic Control 12 26.5±1.3** >33.3**
Diabetic Lutein 12 27.2±1.4** 32.6±1.8**




Fig. 1 Diabetes-induced oxidative stress in the retina was reduced
by lutein. a DHE staining in the retinal section. Original magnifica-
tion ×200; scale bar, 30 μm. b Fluorescence intensity in the INL
relative to that of non-diabetic mice, measured by the Image J
program. Note that ROS increased throughout the retina of mice
diabetic for 1 month; however, this change was prevented by constant
intake of lutein from the onset of diabetes. Non-diabetic mice, n=4;
diabetic mice fed control diet, n=4; diabetic mice fed lutein diet, n=5.
Values are means±SD. *p<0.05, **p<0.01
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by constant lutein intake from the onset of diabetes. No
noteworthy changes in the implicit time of OPs and in the
a- or b-waves were detected in either the non-diabetic mice
and diabetic mice, and this was also the case after lutein
treatment (data not shown).
Therefore, constant intake of the antioxidant lutein
protected the inner retina from the functional deficits
usually induced by diabetes.
Diabetes-induced ERK activation and reduction in
synaptophysin were suppressed by lutein intake To eluci-
date lutein’s effect on ERK activation, we performed
immunoblot analyses of phosphorylated (i.e. activated) ERK.
The activation of ERK in the retina of 1-month-diabetic mice
was significantly inhibited by lutein intake (Fig. 3a, d).
Next, we analysed the synaptic vesicle protein synapto-
physin, which plays a critical role in the cellular source of
OPs. Immunoblot analysis showed that the synaptophysin
protein level was reduced 1 month after diabetes onset
(Fig. 3b, e). However, constant lutein intake from the onset
of diabetes preserved the synaptophysin level. In the retina
of non-diabetic mice fed the lutein-supplemented diet,
levels of activated ERK and synaptophysin were not
changed (data not shown).
Thus, in the diabetic retina, ERK activation and
subsequent synaptophysin reduction were inhibited by
constant lutein intake.
Diabetes-induced reduction in BDNF was suppressed by
lutein intake Since diabetes decreases one of the major
trophic factors for retinal neurons, BDNF, we also
measured BDNF by immunoblot analysis in the 1-month-
diabetic retina. Importantly, the decrease in BDNF caused
by diabetes was attenuated by constant intake of the lutein-
supplemented diet (Fig. 3c, f).
Diabetes-induced histological changes in the inner retina
were suppressed by lutein We next analysed the retinas of
4-month-diabetic mice which had been fed either the lutein
or the control diet from the onset. The thickness of the retinal
layers were measured in paraffin sections and each thickness
was normalised to ONL thickness, as described in the
“Methods”. The normalised thickness of the IPL, where
neurites and the synapses of inner retinal cells are present,
was significantly reduced in the retina of 4-month-diabetic
mice; however, the change was clearly avoided in the retina
of the lutein-fed diabetic mice (Fig. 4a). Moreover, the
normalised INL thickness was reduced (Fig. 4a), suggesting
that INL cells were decreased, and GCL cell numbers also
declined (Fig. 4b) in the retinas of 4-month-diabetic mice that
had been fed the control diet. However, the cell loss was sig-
nificantly suppressed by long-term lutein intake (Fig. 4a, b).
Therefore, these data showed that the diabetes-induced
reduction in inner retinal cells and their neurites was
prevented by constant intake of lutein.
Diabetes-induced apoptosis was inhibited by lutein We
further analysed the levels of apoptosis markers in the retinas
of 4-month-diabetic mice. Cleaved caspase-3, the activated
form, was clearly upregulated in GCL cells and weakly in
INL cells in the retina of diabetic mice (Fig. 5a, c,
arrowheads in a). Moreover, TUNEL-positive cells were
also clearly observed in the GCL (Fig. 5b, d, arrowheads in
b). However, the number of caspase-3-activated or TUNEL-
positive cells in the GCL were significantly reduced in the
lutein-fed diabetic mice, indicating that the apoptosis
induced in the diabetic retina was suppressed by constant
intake of lutein.
Fig. 2 Diabetes-induced visual dysfunction was suppressed by lutein.
Representative wave responses from an individual mouse in each
group to one flash (a). Constant lutein intake from the onset of
diabetes significantly inhibited the reduction of OP3 and total OPs
(ΣOPs; summation of OP2, 3, and 4) amplitude in 1-month-diabetic
mice (b). Black columns, non-diabetic mice, n=5; white columns,
diabetic mice fed control diet, n=6; grey columns, diabetic mice fed
lutein diet, n=6. Values are means±SD. *p<0.05
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Discussion
We have demonstrated that diabetes-induced oxidative
stress in the retina is reduced by a constant intake of lutein
(Fig. 1) without changing body weight or blood glucose
levels (Table 1). Importantly, impairment of visual function
measured by OPs of the ERGs (Fig. 2), as well as ERK
activation, the subsequent synaptophysin reduction and
BDNF depletion after 1 month of diabetes, were all
suppressed by lutein (Fig. 3). Later, at 4 months of diabetes,
histological changes (Fig. 4) caused by apoptosis (Fig. 5) in
the retina of diabetic mice were inhibited by feeding the
lutein-supplemented diet all the time after onset of diabetes.
Superoxide anion can be generated in the mitochondria
under high glucose [26]. However, lutein prevented
oxidative stress in the retina of diabetic mice without body
weight or blood glucose level changes (Table 1), suggesting
that lutein may have scavenged ROS, at least in the retinal
cells. This is consistent with the fact that lutein is delivered
into the IPL, which consists of the neurites of inner retinal
cells, as well as photoreceptor cells [27, 28].
In accord with clinical and experimental data [8, 11, 13,
29], OPs in ERGs were changed in early diabetes. Pharma-
cological studies using tetrodotoxin and glycine suggested the
cellular origin of OPs as neurons with synapse formation in
the inner retina [30–32]. Lack of synaptophysin induces a
decrease in synaptic vesicles, which disturbs neurotransmitter
release and synaptic network activity [33]. Thus, the present
data showing that OPs were preserved when synaptophysin
levels were rescued by ROS reduction are realistic.
In addition, it should be also noted that synaptic activity
promotes cell survival [34, 35] and vision protection in the
following phase (discussed below), through increasing the
levels of intracellular calcium ion in neurons, which are
triggered by synaptic activity, i.e. the neuronal electric
stimuli [34, 35].
Our results showed that ERK activation was suppressed
and the synaptophysin level was preserved when the ROS
level was decreased by lutein (Figs 1 and 3), indicating that
ROS activated ERK to reduce synaptophysin levels in
diabetes, as AT1R signalling did in our previous study [8].
In cardiac fibroblasts, angiotensin II increases the intracel-
lular ROS and ERK activation through AT1R, to induce
cardiac hypertrophy. The increase is cancelled by the
NADH/NADPH oxidase inhibitor that reduces intracellular
ROS, indicating that angiotensin II stimulates ROS pro-
duction via AT1R and NADH/NADPH oxidase, to activate
ERK [36]. Thus, ROS generation in the diabetic retina may
have promoted ERK activation downstream of angiotensin
II, and lutein inhibited this AT1R-mediated diabetic change
in the retina.
We also found that reduction of BDNF was attenuated
by lutein, indicating that this change was partly caused by
excessive oxidative stress. Since BDNF is regulated by
neuronal synaptic activity [37, 38], the positive effect of
lutein on BDNF may have been through preservation of the
synaptophysin level and the subsequent neuronal synaptic
activity in the retina of diabetic mice.
As regards the roles of BDNF, it regulates neurotrans-
mitter release and neuronal activity [38, 39]. Thus, BDNF
Fig. 3 Diabetes-induced biochemical changes in the retina are
prevented by lutein as shown by immunoblot analysis. a, d Diabetes-
induced ERK activation detected by ERK phosphorylation (pERK) in
the retina of 1-month-diabetic mice was prevented by constant intake
of lutein. Non-diabetic mice, n=8; diabetic mice fed control diet, n=8;
diabetic mice fed lutein diet, n=7. b, e A decrease in synaptophysin in
the retina of 1-month-diabetic mice was prevented by constant intake
of lutein. Non-diabetic mice, n=6; diabetic mice fed control diet, n=6;
diabetic mice fed lutein diet, n=6. c, f The level of BDNF was also
reduced in the retina of 1-month-diabetic mice, and was significantly
rescued by constant intake of lutein. Non-diabetic, mice n=6; diabetic
mice fed control diet, n=6; diabetic mice fed lutein diet, n=6. Bar graph
values are relative to those of the non-diabetic controls. Values are
means±SD. *p<0.05, **p<0.01
976 Diabetologia (2010) 53:971–979
reduction may also have been involved in visual impair-
ment shown by OPs in ERGs. Another role of BDNF is to
promote survival of inner retinal cells [19, 40]. Thus, this
oxidative stress-mediated BDNF reduction may, to some
extent, have contributed to the obvious histological changes
subsequently appearing in the inner retina.
Histological changes in the inner retina were clearly
observed in 4-month-diabetic mice (Figs 4 and 5).
Consistent with previous reports showing caspase-3 activa-
tion and TUNEL staining [16, 18, 41, 42], cell loss in the
STZ-induced diabetic retina of this study was also through
apoptosis pathway. This long-term effect may be caused by
multiple signals activated by diabetes. However, lutein’s
ability to maintain synaptophysin levels and neuronal network
activity (discussed above), together with the resulting main-
tenance of BDNF production, may be involved in promoting
the survival of neurons in the inner retina, interrupting the
positive feedback loop for progressive neurodegeneration.
Interestingly, in another progressive neurodegenerative dis-
ease, Alzheimer’s disease, reductions in synaptophysin [43]
and BDNF [44] are also observed, and oxidative stress is
involved in the pathogenesis. However, whether or not lutein
will have any effect on the progression of Alzheimer’s
disease is still unknown.
Taken as a whole, the current evidence clearly indicates
that the visual impairment occurring in early diabetes is
regulated by oxidative stress, which was prevented by
constant lutein intake.
The relationship between a lutein diet and eye disease has
been mainly analysed in human age-related macular degener-
ation (AMD) and cataract [45]. AMD may partly be
exacerbated by blue light (the blue-light hazard), and lutein
may act as a blue-light filter to prevent subsequent photo-
chemical injury to the retina that is mediated by oxidative
stress. Several previous human studies have suggested, and a
large-scale clinical study (the Age-Related Eye Disease Study
Fig. 5 Diabetes-induced apoptosis was inhibited by lutein. a Caspase-
3 activation detected by immunohistochemistry of cleaved caspase-3.
Caspase-3 activation was obvious in GCL and weak in INL cells of 4-
month-diabetic retinas (arrowheads, cleaved caspase-3-positive cells);
however, the activation was suppressed by constant intake of lutein. b
TUNEL staining in the GCL of 4-month-diabetic retinas (arrowheads)
was also suppressed by lutein treatment. Cleaved caspase-3-positive
cells (c) and the TUNEL-positive cells (d) in GCL were counted. a, c
Non-diabetic mice, n=4; diabetic mice fed control diet, n=4; diabetic
mice fed lutein diet, n=4. b, d Non-diabetic mice, n=5; diabetic mice
fed control diet, n=6; diabetic mice fed lutein diet, n=6. Value are
means±SD. *p<0.05, **p<0.01. a Original magnification ×200, scale
bar, 30 μm. b Original magnification ×400; scale bar, 40 μm
Fig. 4 Diabetes-induced histological changes were suppressed by
lutein. Thickness of each retinal layer was measured in paraffin sections
after haematoxylin and eosin staining. Original magnification ×400. a
Relative thicknesses of IPL and INL, normalised to ONL measured at
the same point, respectively, were reduced in the retina of 4-month-
diabetic mice, but remained normal in the diabetic mice fed the lutein
diet all the time from diabetes onset. b The neuronal cell number in
the GCL in one cross-section of the mice diabetic for 4 months was
decreased; however, this change was significantly suppressed by
lutein. Black columns, non-diabetic mice, n=6; white columns,
diabetic mice fed control diet, n=5; grey columns, diabetic mice fed
lutein diet, n=5. Values are means±SD. *p<0.05, **p<0.01
Diabetologia (2010) 53:971–979 977
2) is now ongoing, to show the effect of lutein in reducing risk
of progression of AMD, which is, at least in part, accelerated
by light exposure [46]. But, the present animal study showed
that lutein does have the effect, in vivo, of suppressing
oxidative stress independently of blue-light exposure. This
antioxidative effect is also reported in another field: increase in
dietary intake of lutein is protective against the development
of early atherosclerosis from the results of epidemiological
human data, and in vitro and in vivo mouse model experi-
ments [21]. Future clinical studies aimed at analysing the
effect of a daily lutein administration in human diabetic
retinopathy are anticipated. Other epidemiological data,
showing that a higher plasma concentration of lutein/
zeaxanthin and lycopene is associated with significantly lower
odds of diabetic retinopathy [47], may also support this idea.
In summary, we have shown that lutein prevents diabetes-
induced visual dysfunction caused by damage to the inner
neural retina that ultimately leads to retinal cell death. Lutein
inhibited oxidative stress, thereby preserving the neuro-
protective pathways in the early diabetic retina.
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